Icosagen Cell Factory OÜ

Icosagen develops antibody therapeutics against cancer, pain and COVID-19. We have two antibody drug candidates targeting SARS-CoV-2 moving into clinics. However, it takes time and until we get the antibody treatment to COVID patients, we have another solution. We have developed a nasal spray BioBlock that contains bovine antibodies against SARS-CoV-2. These antibodies are manufactured from cow’s milk and colostrum that had been “vaccinated”. BioBlock is not a medicine, it is rather a consumer product, where antibodies are acting locally as nanoparticles inactivating specifically coronavirus SARS-CoV-2 on nasal mucosa.

Our mission it to bring academic research out from the lab and translate it into better treatments and diagnostics.

Icosagen is a leading research-driven contract research provider for biopharmaceutical and biotechnology industries. Our company is made up of over 100 skilled and committed professionals, almost 30 of them have a PhD degree. We have 100 active clients including most of the top 10 pharma and diagnostic companies. Company’s sales revenue in 2021 reaches over €10 million. The management system complies with the requirements of the ISO 9001:2015 standard.
For our customers, we provide opportunities and contributions to make their activities simpler and more effective, more efficient and less risky. We continuously develop and improve our products, technologies and services to provide additional innovation and benefit to our customers.
The Group comprises four entities: parent company Icosagen AS and three subsidiaries: Icosagen Cell Factory OÜ, Icosagen Technologies Inc., and IcoPark OÜ.
In the last years, Icosagen has invested much of its resources in developing medicines and other measures against the SARS-CoV-2 virus. One of these measures is BioBlock® nasal spray. The conception and development of BioBlock® is made in collaboration with following partners: Icosagen Cell Factory OÜ, AS Chemi-Pharm, OÜ Teadus ja Tegu, University of Tartu, Estonian University of Life Sciences. A USPTO patent application (No. 63/160,833) has been submitted by the product developers that covers the manufacturing process.
Icosagen Cell Factory OÜ was established in 2005. It belongs to top 5 CRO (Contract Research Organization)-type companies in Europe, developing novel technologies and providing research services to the biopharmaceutical and biotechnology industries and to academia. A portfolio of proprietary technologies (e.g. QMCF Technology for protein production) and custom-tailored services e.g. recombinant protein production, antibody and cell line development are offered by Icosagen Cell Factory.
BioBlock® nasal spray is a natural product that contains antibodies against SARS-CoV-2 along with naturally occurring beneficial antibodies in colostrum which humans benefit daily while consuming dairy and meat products. In vitro testings demonstrated that the product blocks the entry of viral particles into cells. Tests were performed against initial Wuhan and newly mutated SARS-CoV-2 variants. It is an additional method meant to prevent the spread of SARS-CoV-2 virus. BioBlock® works on the surface of the mucous membranes in the nasopharynx and can be used wherever it is difficult to distance from others.
In Estonia, BioBlock® has been classifies as a regular consumer product by the authorities. Since BioBlock® is a borderline product, we are applying for classification and awaiting the decisions from the authorities of several countries. We are currently working on bringing BioBlock to people in the whole world to help fight the global pandemic.